ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Exelixis, Bayer and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Exelixis×Bayer×Novartis×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ExelixisBayerNovartis
studies on the registry571,6943,900
open to participants now1160211
phase 3 studies under way101194
reach primary completion within a year635125
programswith a study of their own in two years42177+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseExelixisBayerNovartis
Phase 150%19%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 200%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
Phase 3

Exelixis: 1 of its 4 programs at phase 3

  1. zanzalintinibphase 3
25%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

Exelixis: 1 of its 4 programs at approved, new studies

  1. cabozantinibapproved, new study
25%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Exelixis2 readouts · 1 phase 3·

Exelixis, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zanzalintinibphase 3 · Dec 15 · NCT05678673
····

Exelixis, May ’27: 1 program whose next study reaches primary completion

  1. Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628phase 1 · May 31 · NCT06952010
·····
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Exelixis

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 18 in all. A program counts in each condition its studies name most.

ConditionExelixisBayerNovartis
Prostatic Neoplasmsall three · compare here

Exelixis in Prostatic Neoplasms: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Prostatic Neoplasms in search

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Exelixis in Carcinoma, Non-Small-Cell Lung: 1 program

  1. zanzalintinibphase 3

Their studies: Exelixis’s studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsall three · compare here

Exelixis in Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Neoplasms in search

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

Colorectal Neoplasmsall three · compare here

Exelixis in Colorectal Neoplasms: 1 program

  1. zanzalintinibphase 3

Their studies: Exelixis’s studies of Colorectal Neoplasms in search

Bayer in Colorectal Neoplasms: 1 program

  1. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Renal Insufficiency, Chronic2 of 3 · compare here–

Bayer in Renal Insufficiency, Chronic: 2 programs

  1. nurandociguatphase 2
  2. finerenoneapproved, new study

Their studies: Bayer’s studies of Renal Insufficiency, Chronic in search

Novartis in Renal Insufficiency, Chronic: 2 programs

  1. Atrasentanphase 3
  2. OJR520phase 1

Their studies: Novartis’s studies of Renal Insufficiency, Chronic in search

Atrial Fibrillation2 of 3 · compare here–

Bayer in Atrial Fibrillation: 1 program

  1. BAY 3670549phase 2

Their studies: Bayer’s studies of Atrial Fibrillation in search

Novartis in Atrial Fibrillation: 2 programs

  1. abelacimabphase 3
  2. PKN605phase 2

Their studies: Novartis’s studies of Atrial Fibrillation in search

Carcinoma, Renal Cell2 of 3 · compare here

Exelixis in Carcinoma, Renal Cell: 2 programs

  1. zanzalintinibphase 3
  2. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Carcinoma, Renal Cell in search

–

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Cardiovascular Diseases2 of 3 · compare here–

Bayer in Cardiovascular Diseases: 1 program

  1. Aspirinapproved, new study

Their studies: Bayer’s studies of Cardiovascular Diseases in search

Novartis in Cardiovascular Diseases: 2 programs

  1. pelacarsenphase 3
  2. DII235phase 2

Their studies: Novartis’s studies of Cardiovascular Diseases in search

Coronary Artery Disease2 of 3 · compare here–

Bayer in Coronary Artery Disease: 2 programs

  1. nurandociguatphase 2
  2. Aspirinapproved, new study

Their studies: Bayer’s studies of Coronary Artery Disease in search

Novartis in Coronary Artery Disease: 1 program

  1. YMI024phase 2

Their studies: Novartis’s studies of Coronary Artery Disease in search

Schizophrenia2 of 3 · compare here–

Bayer in Schizophrenia: 1 program

  1. elinzanetantphase 3

Their studies: Bayer’s studies of Schizophrenia in search

Novartis in Schizophrenia: 2 programs

  1. GXV-813phase 2
  2. XEP527phase 1

Their studies: Novartis’s studies of Schizophrenia in search

Bulbo-Spinal Atrophy, X-Linked2 of 3 · compare here–

Bayer in Bulbo-Spinal Atrophy, X-Linked: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Bulbo-Spinal Atrophy, X-Linked in search

Novartis in Bulbo-Spinal Atrophy, X-Linked: 1 program

  1. tulmimetostatphase 2

Their studies: Novartis’s studies of Bulbo-Spinal Atrophy, X-Linked in search

Carcinoma, Hepatocellular2 of 3 · compare here

Exelixis in Carcinoma, Hepatocellular: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Carcinoma, Hepatocellular in search

–
Diabetic Nephropathies2 of 3 · compare here–

Bayer in Diabetic Nephropathies: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Diabetic Nephropathies in search

Novartis in Diabetic Nephropathies: 1 program

  1. Atrasentanphase 3

Their studies: Novartis’s studies of Diabetic Nephropathies in search

Glioblastoma2 of 3 · compare here

Exelixis in Glioblastoma: 1 program

  1. cabozantinibapproved, new study

Their studies: Exelixis’s studies of Glioblastoma in search

–

Novartis in Glioblastoma: 1 program

  1. Lutetium-177phase 2

Their studies: Novartis’s studies of Glioblastoma in search

Heart Failure2 of 3 · compare here–

Bayer in Heart Failure: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Heart Failure in search

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Neoplasm Metastasis2 of 3 · compare here

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

–
Prostatic Neoplasms, Castration-Resistant2 of 3 · compare here–

Bayer in Prostatic Neoplasms, Castration-Resistant: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms, Castration-Resistant in search

Novartis in Prostatic Neoplasms, Castration-Resistant: 1 program

  1. luxdegalutamidephase 2

Their studies: Novartis’s studies of Prostatic Neoplasms, Castration-Resistant in search

Rosacea2 of 3 · compare here–

Bayer in Rosacea: 1 program

  1. Oxymetazolinephase 2

Their studies: Bayer’s studies of Rosacea in search

Novartis in Rosacea: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Rosacea in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Exelixis 4 of 4 · Bayer 13 of 21 · Novartis 56 of 77 programs (33 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).